Oral Solithromycin Versus Oral Moxifloxacin For Treatment Of Adult Community-Acquired Bacterial Pneumonia (cabp): Results Of The Global Phase-3 Trial Solitaire-Oral

被引：0
|
作者：
Oldach, D. W. [1 ]
Barrera, C. M. [2 ]
Metev, H. [3 ]
Dvoretskiy, L. I. [4 ]
Mykietiuk, A. [5 ]
Mitha, I. [6 ]
De Salvo, M. C. [7 ]
Tanaseanu, C. M. [8 ]
Szabo, P. [9 ]
Clark, K. [1 ]
Jamieson, B. [1 ]
Das, A. [10 ]
Keedy, K. [1 ]
Fernandes, P. [1 ]
机构：
[1] Cempra Pharmaceut Inc, Chapel Hill, NC USA
[2] A&L Clin Res, Miami, FL USA
[3] Dr Dimitar Gramatikov Hosp Pulm Dis, Ruse, Bulgaria
[4] City Clin Hosp 7, Moscow, Russia
[5] Inst Med Platense, La Plata, Buenos Aires, Argentina
[6] World Wide Clin Trials, Benoni, South Africa
[7] Ctr Med Dra De Salvo, Buenos Aires, DF, Argentina
[8] St Pantelimon Emergency Clin Hosp, Bucharest, Romania
[9] Univ Teaching Hosp, Nyiregyhaza, Hungary
[10] InClin Inc, San Francisco, CA USA
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2015年 / 191卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A6424
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Solitaire-Iv: Results Of A Phase 3 Iv To Oral Trial In Adults With Community-Acquired Bacterial Pneumonia Comparing Solithromycin To Moxifloxacin
    File, T. M., Jr.
    Rewerska, B.
    Tanaseanu, C. M.
    Mihailovic-Vucinic, V.
    Gonong, J. R.
    Jamieson, B. D.
    Taylor, D.
    Sheets, A.
    Keedy, K.
    Oldach, D. W.
    Fernandes, P.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 193
  • [2] Efficacy and safety of oral solithromycin versus oral moxifloxacin for treatment of community-acquired bacterial pneumonia: a global, double-blind, multicentre, randomised, active-controlled, non-inferiority trial (SOLITAIRE-ORAL)
    Barrera, Carlos M.
    Mykietiuk, Analia
    Metev, Hristo
    Nitu, Mimi Floarea
    Karimjee, Najumuddin
    Doreski, Pablo Alexis
    Mitha, Ismail
    Tanaseanu, Cristina Mihaela
    Molina, Joseph McDermott
    Antonovsky, Yuri
    Van Rensburg, Dirkie Johanna
    Rowe, Brian H.
    Flores-Figueroa, Jose
    Rewerska, Barbara
    Clark, Kay
    Keedy, Kara
    Sheets, Amanda
    Scott, Drusilla
    Horwith, Gary
    Das, Anita F.
    Jamieson, Brian
    Fernandes, Prabhavathi
    Oldach, David
    LANCET INFECTIOUS DISEASES, 2016, 16 (04): : 421 - 430
  • [3] LATE-BREAKING ABSTRACT: Oral solithromycin has a favorable profile versus oral moxifloxacin for treatment of adult community-acquired pneumonia (CABP) in elderly patients and those with COPD or asthma
    Oldach, David
    Luna, Carlos
    Szabo, Peter
    Mitha, Ismail
    Tanaseanu, Cristina
    Doreski, Alexis
    Barrera, Carlos
    Das, Anita
    Keedy, Kara
    Jamieson, Brian
    Fernandes, Prabhavathi
    EUROPEAN RESPIRATORY JOURNAL, 2015, 46
  • [4] Results from a Phase 3 trial in Moderate to Moderately Severe Community Acquired Bacterial Pneumonia (CABP) Treated As Outpatients With a New Oral Macrolide, Solithromycin
    Oldach, David
    Barrera, Carlos
    Rowe, Brian
    Nitu, Floarea Mimi
    Mykietiuk, Analia
    Metev, Hristo
    Laabs, Jessica
    Mitha, Ismail
    Tanaseanu, Cristina Mihaela
    Molina, Joseph McDermott
    Antonovsky, Yuri
    Van Rensburg, Dirkie Johanna
    Flores, Jose
    Sokolowska, Barbara
    Doreski, Alexis
    Das, Anita
    Clark, Kay
    Jamieson, Brian
    Sheets, Amanda
    Keedy, Kara
    Fernandes, Prabhavathi
    CHEST, 2015, 148 (04)
  • [5] SOLITAIRE-IV: A Randomized, Double-Blind, Multicenter Study Comparing the Efficacy and Safety of Intravenous-to-Oral Solithromycin to Intravenous-to-Oral Moxifloxacin for Treatment of Community-Acquired Bacterial Pneumonia
    File, Thomas M., Jr.
    Rewerska, Barbara
    Vucinic-Mihailovic, Violeta
    Gonong, Joven Roque V.
    Das, Anita F.
    Keedy, Kara
    Taylor, David
    Sheets, Amanda
    Fernandes, Prabhavathi
    Oldach, David
    Jamieson, Brian D.
    CLINICAL INFECTIOUS DISEASES, 2016, 63 (08) : 1007 - 1016
  • [6] Efficacy of Delafloxacin versus Moxifloxacin against Bacterial Respiratory Pathogens in Adults with Community-Acquired Bacterial Pneumonia (CABP): Microbiology Results from the Delafloxacin Phase 3 CABP Trial
    McCurdy, Sandra
    Keedy, Kara
    Lawrence, Laura
    Nenninger, Ashley
    Sheets, Amanda
    Quintas, Megan
    Cammarata, Sue
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2020, 64 (03)
  • [7] The pharmacokinetic evaluation of omadacycline (Oral Only Dosing Regimen) for the treatment of Community-Acquired Bacterial Pneumonia (CABP)
    Cilloniz, Catia
    Torres, Antoni
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2023, 19 (09) : 569 - 576
  • [8] The efficacy and safety of two oral moxifloxacin regimens compared to oral clarithromycin in the treatment of community-acquired pneumonia
    Hoeffken, G
    Meyer, HP
    Winter, J
    Verhoef, L
    RESPIRATORY MEDICINE, 2001, 95 (07) : 553 - 564
  • [9] Efficacy of delafloxacin versus moxifloxacin against atypical bacterial respiratory pathogens in adults with community-acquired bacterial pneumonia (CABP): Data from the Delafloxacin Phase 3 CABP Trial
    McCurdy, Sandra
    Nenninger, Ashley
    Sheets, Amanda
    Keedy, Kara
    Lawrence, Laura
    Quintas, Megan
    Cammarata, Sue
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2020, 97 : 374 - 379
  • [10] DELAFLOXACIN IN THE TREATMENT OF COMMUNITY-ACQUIRED BACTERIAL PNEUMONIA: OUTCOMES FROM A GLOBAL PHASE-3 STUDY
    Cammarata, Sue
    Horcajada, Juan P.
    Alvarez-Sala, Rodolfo
    Nitu, Floarea-Mimi
    Quintas, Megan
    Lawrence, Laura
    Li, Yang
    CHEST, 2019, 156 (04) : 412A - 413A
12345